Table 1.
MAFLD HCC prevalence
| Patient group | Sample size (number of studies) | MAFLD prevalence (%) (95% CI) | I2 (%) | Cochran’s Q |
|---|---|---|---|---|
| Single-MAFLD HCC | ||||
| Overall prevalence | 39,381 (11) | 12.4 (8.3–17.3) | 99.1 | <0.01 |
| Geographical Region | ||||
| Central America | 547 (1) | 30.0 (26.2–33.9) | N/A | N/A |
| Australia | 225 (3) | 19.4 (8.5–33.0) | 78 | 0.01 |
| North America | 23,245 (1) | 18.2 (17.7–18.7) | N/A | N/A |
| Europe | 8,736 (2) | 11.5 (5.7–19.0) | 97.3 | <0.01 |
| Asia | 6,628 (4) | 5.3 (3.6–7.4) | 89.3 | <0.01 |
| Clinical phenotype | ||||
| MAFLD with T2DM | 5,691 (5) | 52.1 (30.1–73.7) | 97.7 | <0.01 |
| Lean MAFLD | 5,690 (5) | 31.4 (24.9–38.4) | 84.1 | <0.01 |
| Mixed-MAFLD HCC | ||||
| Overall prevalence | 51556 (17) | 41.3 (34.3–48.5) | 99.5 | <0.01 |
| Geographic region | ||||
| North America | 23,245 (1) | 63.6 (63.0–64.2) | N/A | N/A |
| Europe | 8,914 (4) | 53.8 (43.2–64.3) | 96.3 | <0.01 |
| Asia | 19,260 (11) | 37.2 (27.6–47.4) | 99.1 | <0.01 |
| Australia | 137 (1) | 17.5 (11.6–24.4) | N/A | N/A |
| Primary liver disease | ||||
| HBV | 20,166 (12) | 40.0 (30.2–50.3) | 99.2 | <0.01 |
| HCV | 13,090 (5) | 54.2 (40.4–67.6) | 99.3 | <0.01 |
| ALD | 6,841 (5) | 64.3 (52.7–75.0) | 97.7 | <0.01 |
| Clinical phenotype | ||||
| MAFLD with T2DM | 26,548 (9) | 35.6 (26.3–45.4) | 97.4 | <0.01 |
| Lean-MAFLD | 25,934 (7) | 21.2 (9.8–35.5) | 99.9 | <0.01 |
| Total-MAFLD HCC | ||||
| Overall prevalence | 33,590 (8) | 48.7 (34.6–63.0) | 99.7 | <0.01 |
| Total-MAFLD phenotype | ||||
| MAFLD with T2DM | 32,169 (11) | 34.7 (25.9–44.0) | 98.6 | <0.01 |
| Lean-MAFLD | 31,373 (9) | 21.7 (12.6–32.6) | 99.8 | <0.01 |
MAFLD, metabolic dysfunction-associated fatty liver disease; HCC, hepatocellular carcinoma; CI, confidence interval; T2DM, type 2 diabetes mellitus; HBV, hepatitis B virus; HCV, hepatitis C virus; ALD, alcohol-related liver disease.